pharmaphorum12h
Troubled gene therapy player bluebird sold for a song
12 years after going public, beleaguered gene therapy company bluebird bio will be sold to private equity groups Carlyle and ...
What's Going On With Gene Therapy Company Bluebird Bio Stock Today?
Bluebird Bio, Inc. (NASDAQ:BLUE), on Friday, entered into a definitive agreement to be acquired by global investment firms ...
FiercePharma3d
Once valued at $10B, bluebird bio sold to private equity firms for $29M
There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...
Bluebird bio stock slides for second day on buyout news
Bluebird bio (BLUE) shares continued their downward descent Monday following news that the company plans to be taken private through a deal valued at up to $96M. Read more here.
Once a darling of biotech, bluebird sells for less than $30M upfront
Somerville gene therapy company bluebird bio, once among the highest-profile biotechs in the Boston area, has agreed to be ...
Struggling Somerville biotech Bluebird Bio to be sold for less than $30 million
Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...
GEN1d
StockWatch: Bluebird Bio Plunges on Buyout, as Gene Therapy’s Woes Grow
Like other developers of recently approved gene therapies, Bluebird has been slow to generate demand for its products. That reflects challenges in securing reimbursement from payers stemming from ...
Title: bluebird bio Announces Positive Phase 1/2 Clinical Trial Data for Gene Therapy
In recent financial reports submitted to the Securities and Exchange Committee (SEC) in an 8-K filing, bluebird bio, Inc. (NASDAQ: BLUE), a leading biotech company, has provided an update on their ...
pharmaphorum10h
Pfizer drops Beqvez, leaving gene therapy cupboard bare
Beqvez was Pfizer's first gene therapy, stemming from an alliance with Spark Therapeutics (now part of Roche) more than a ...